PF-04455242
Investigational drug
| PF-04455242 | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 956905-27-4 |
| PubChem | 16005106 |
| DrugBank | |
| ChemSpider | 13180813 |
| KEGG | D09992 |
PF-04455242 is an investigational drug that was developed by Pfizer for the treatment of cognitive disorders such as schizophrenia and Alzheimer's disease. It acts as a selective dopamine receptor D1 antagonist.
Pharmacology[edit | edit source]
PF-04455242 is designed to target the dopamine receptor D1, which is implicated in various neurological disorders. By antagonizing this receptor, PF-04455242 aims to modulate the dopaminergic system, potentially improving cognitive function in patients with disorders like schizophrenia and Alzheimer's disease.
Mechanism of Action[edit | edit source]
The drug functions by selectively binding to the D1 subtype of dopamine receptors, inhibiting their activity. This action is thought to help in balancing the dopaminergic activity in the brain, which is often disrupted in cognitive disorders. The modulation of D1 receptors is believed to enhance working memory and executive function, which are typically impaired in these conditions.
Development and Research[edit | edit source]
PF-04455242 has undergone various stages of clinical trials to assess its efficacy and safety. Initial studies focused on its potential benefits in improving cognitive deficits associated with schizophrenia. However, the development of PF-04455242 has faced challenges, including the complexity of targeting specific dopamine receptors without affecting others, which can lead to side effects.
Potential Applications[edit | edit source]
The primary focus of PF-04455242 is on cognitive enhancement in disorders like schizophrenia and Alzheimer's disease. By improving cognitive functions, the drug could potentially enhance the quality of life for patients suffering from these debilitating conditions. However, further research is needed to fully understand its efficacy and safety profile.
Challenges and Considerations[edit | edit source]
Developing drugs that target the dopaminergic system is challenging due to the intricate balance required to avoid side effects. The specificity of PF-04455242 for the D1 receptor is crucial in minimizing unwanted interactions with other dopamine receptors, which could lead to adverse effects.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
